Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
17 hedge funds and large institutions have $216K invested in Titan Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
2,067% more call options, than puts
Call options by funds: $65K | Put options by funds: $3K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
13% more funds holding
Funds holding: 15 → 17 (+2)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
80% less capital invested
Capital invested by funds: $1.1M → $216K (-$885K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$62.7K |
| 2 |
HF
HRT Financial
New York
|
+$14.9K |
| 3 |
Goldman Sachs
New York
|
+$8.56K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$89K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$37K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29.3K |
| 4 |
VF
Virtu Financial
New York
|
-$3.61K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$451 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $146K | -$29.3K | -65 | -7% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $22K | – | – | – |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $22K | +$62.7K | +139 | New |
|
|
VF
4
Virtu Financial
New York
| $9K | -$3.61K | -8 | -12% |
|
|
HF
5
HRT Financial
New York
| $5K | +$14.9K | +33 | New |
|
6
Northern Trust
Chicago,
Illinois
| $4K | – | – | – |
|
|
WPA
7
Winning Points Advisors
Boca Raton,
Florida
| $3K | -$451 | -1 | -5% |
|
|
8
Goldman Sachs
New York
| $3K | +$8.56K | +19 | New |
|
|
9
Bank of America
Charlotte,
North Carolina
| $2K | +$1.35K | +3 | +30% |
|
|
APA
10
American Portfolios Advisors
Holbrook,
New York
| $123 | – | – | – |
|
|
ARTA
11
A.R.T. Advisors
New York
| – | -$89K | -116 | Closed |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$37K | -82 | Closed |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$451 | -1 | -33% |
|
|
SFS
14
Sowell Financial Services
North Little Rock,
Arkansas
| – | +$451 | +1 | New |
|
TTNP Hedge Fund Activity: Q3 2019 in Review
17 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2019, worth a combined $216K — down 80% from $1.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TTNP positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $62.7K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $89K sold.
- 17 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2019, up from 15 in Q2 2019.
- Funds reported $216K of Titan Pharmaceuticals stock for Q3 2019, down 80% quarter-over-quarter.
- 4 funds opened new Titan Pharmaceuticals positions in Q3 2019 and 2 closed out, a net change of +2 holders.
- The largest Titan Pharmaceuticals buyer in Q3 2019 was Sabby Management, an estimated $62.7K added.
- The largest Titan Pharmaceuticals seller in Q3 2019 was A.R.T. Advisors, an estimated $89K sold.
Based on aggregated 13F filings for Q3 2019.